Molecular detection of pathogenic microorganisms can determine patient's condition by detecting the genes of pathogenic microorganisms and conducting genotyping so as to develop effective prevention and treatment measures.

Human papilloma virus (HPV) genotyping detection

BGI Health can conduct accurate genotyping for 14 kinds of recognized high-risk HPV and 2 kinds of common low-risk HPV by using flight time mass-spectrometric technique / high-throughput sequencing technology platform. With high sensitivity, high specificity, high throughput and genotyping, this detection technology is an ideal detection platform for clinical hospitals and large-scale cervical cancer screening program.

Hepatitis B virus resistance and genotyping detection

BGI Health can detect the variation information of 11 drug resistance sites related to six nucleoside (acid) antiviral drugs of HBV and distinguish the types of 8 HBV genes (A to H) simultaneously by using sequencing technique. With full understanding of virus information, it can find virus resistance timely and predict disease progression to provide reference for scientific use of medicine and help the development of individualized antiretroviral treatment programs. 

Gene detection for individualized treatment of Hepatitis C

BGI Health can conduct detection for HCV genotyping by applying sequencing technique and comprehensively distinguish 6 main types of HCV and subordinate 19 subtypes. The detection can cover all common types among Chinese population. In addition, BGI Health can also carry out quantitative determination of HCV RNA by using fluorescent quantitation PCR method. HCV genotyping and quantitative detection can be carried out in one clinical gene detection which will predict disease progression, provide instructions for pharmacy and monitor the number and replication of body virus.